Skip to main content
OpenTrials
Completed

NCT Number: NCT02511834

VEST III PMS Clinical Protocol

Post marketing surveillance (PMS) study. 200 patients will be enrolled in a prospective, multi center, randomized, two-arm, open label, and controlled, enrolling patients with multi vessel atherosclerotic coronary artery disease, scheduled to undergo Coronary artery bypass grafting (CABG) with arterial grafting of IMA to LAD, one saphenous vein graft (SVG) to the right territory and one or more SVGs to the left territory. Of all vein grafts, one will be selected randomly to receive treatment with VEST and another designated Control.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Medical University of Innsbruck, Innsbruck, Austria

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient scheduled for on-pump CABG on clinical grounds
  • Two or more bypass vein grafts bypasses indicated as follows: one (1) for right coronary artery, 1 or more for left coronary arteries and IMA indicated for the LAD on clinical grounds
  • Appropriately sized and accessible target coronary arteries, with a minimum diameter of 1.5 mm and adequate vascular bed
  • Ability to give their informed written consent
  • Ability and willingness to comply with study follow up requirements
  • Patient is ≥ 18 and ≤ 80 years of age, and has Life expectancy ≥5 years

Exclusion criteria

  • Concomitant non-CABG cardiac procedure
  • Prior cardiac surgery
  • Emergency CABG surgery (cardiogenic shock, inotropic pressure support, IABP)
  • Contraindication for on-pump CABG with cardioplegic arrest (e.g. severely calcified aorta)
  • Calcification at the intended anastomotic sites, as assessed upon opening of the chest, before randomization
  • Severe vein varicosity
  • Prior debilitating stroke less than 1 year before surgery
  • Severe renal dysfunction (Cr>2.0 mg/dL or >177 μmol/L)
  • Women of child bearing age
  • Concomitant life-threatening disease likely to limit life expectancy to less than 5 years
  • Indication for Warfarin up to time of surgery
  • Inability to tolerate or comply with required normal post-operative drug regimen (antiplatelet, statin and beta-blockers) that cannot adequately be controlled.
  • inability to take aspirin
  • Contraindication to intravascular contrast material that cannot be adequately controlled with pre-medication
  • Inability to comply with required follow-ups including angiographic and/or CT imaging methods.
  • Participating in any other investigational study for either drug or device which can influence collection of valid data under this study

Treatment and study plan

VEST External Support

Device

Coronary artery bypass surgery

Procedure

Other names: CABG

Primary outcomes

  1. Proportion of Vein grafts with Fitzgibbon I patency score out of all grafts including occluded ones.

    Time frame: 2 years

    Perfect patency, no lumen irregularities. Rates out of all grafts including occluded ones.

Secondary outcomes

  1. Intimal hyperplasia area

    Time frame: 2 years

    Sub group (IVUS) - Intimal hyperplasia (plaque+media) area [mm2] as assessed by IVUS

  2. MACCE

    Time frame: 2 years

    Composite of: All-cause mortality; Stroke; Myocardial infarction; Coronary revascularization

  3. Vein graft failure

    Time frame: 2 years

    Defined as ≥50% stenosis by QCA

  4. Early vein graft failure

    Time frame: 6 months

    Early vein graft failure, defined as >50% occlusion by CT Angio

Sponsors and collaborators

Lead sponsor

Vascular Graft Solutions Ltd.

Industry

Registry information

Acronym: VEST III

Important dates

Study start
2015
Primary completion
2019
Study completion
2019
First posted
Jul 30, 2015
Registry last updated
Jun 26, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.